Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

被引：0
|
作者：
Joseph P. Garay
Rebecca Smith
Kaylyn Devlin
Daniel P. Hollern
Tiera Liby
Moqing Liu
Shanta Boddapati
Spencer S. Watson
Amanda Esch
Ting Zheng
Wallace Thompson
Darcie Babcock
Sunjong Kwon
Koei Chin
Laura Heiser
Joe W. Gray
James E. Korkola
机构：
[1] Oregon Health & Science University,Department of Biomedical Engineering
[2] University of North Carolina,Department of Genetics
[3] Chapel Hill,undefined
来源：
Breast Cancer Research | / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Role of EGFR, HER2 and PIK3CA alterations in male breast cancer
    Rizzolo, P.
    Silvestri, V.
    Falchetti, M.
    Zanna, I.
    Palli, D.
    Ottini, L.
    EJC SUPPLEMENTS, 2010, 8 (05): : 24 - 24
  • [32] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Vollbrecht, Claudia
    Hoffmann, Inga
    Lehmann, Annika
    Merkelbach-Bruse, Sabine
    Fassunke, Jana
    Wagener-Ryczek, Svenja
    Ball, Markus
    Dimitrova, Lora
    Hartmann, Arndt
    Stohr, Robert
    Erber, Ramona
    Weichert, Wilko
    Pfarr, Nicole
    Bohlmann, Lisa
    Jung, Andreas
    Dietmaier, Wolfgang
    Dietel, Manfred
    Horst, David
    Hummel, Michael
    VIRCHOWS ARCHIV, 2023, 482 (04) : 697 - 706
  • [33] AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancer
    Sanz, F. Carmona
    Montemurro, F.
    Rossi, V.
    Verma, C.
    Berger, M.
    Baselga, J.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 27 - 28
  • [34] PIK3CA mutations in breast cancer: Mutational landscape and clinical implications in ER+/HER2-subtype
    Ahn, H. K.
    Park, S.
    Hyun, S. H.
    Park, K.
    Lee, E.
    Kim, J-Y
    Nam, S. J.
    Kim, S. W.
    Lee, J. E.
    Lee, S. K.
    Yu, J. H.
    Ahn, J. S.
    Im, Y-H
    Park, Y. H.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Claudia Vollbrecht
    Inga Hoffmann
    Annika Lehmann
    Sabine Merkelbach-Bruse
    Jana Fassunke
    Svenja Wagener-Ryczek
    Markus Ball
    Lora Dimitrova
    Arndt Hartmann
    Robert Stöhr
    Ramona Erber
    Wilko Weichert
    Nicole Pfarr
    Lisa Bohlmann
    Andreas Jung
    Wolfgang Dietmaier
    Manfred Dietel
    David Horst
    Michael Hummel
    Virchows Archiv, 2023, 482 : 697 - 706
  • [36] Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2-metastatic breast cancer: Incidence and outcomes with targeted therapy.
    Dempsey, Naomi
    Bhatt, Priya
    Lewis, Courtney
    Tolman, Dana
    Chamorro, Yolcar
    Rubens, Muni
    Carcas, Lauren
    Sandoval-Leon, Ana Cristina
    Ahluwalia, Manmeet Singh
    Mahtani, Reshma L.
    Harpalani, Natasha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
    Rexer, B. N.
    Chakrabarty, A.
    Rinehart, C.
    Chang, J.
    Engelman, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 266S - 267S
  • [38] Comprehensive Analysis of PIK3CA Mutations and Their Prognostic Implications in Breast Cancer Undergoing Neoadjuvant Therapy
    Zhao, Jianing
    Zhang, Huirui
    Liu, Yueping
    LABORATORY INVESTIGATION, 2025, 105 (03)
  • [39] Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and/or HER2 positive breast cancer
    Garcia-Murillas, I.
    Pearson, A.
    Lambros, M.
    Natrajan, R.
    Segal, C.
    Dowsett, M.
    Turner, N. C.
    CANCER RESEARCH, 2013, 73
  • [40] Cellular senescence within HER2-amplified breast cancer: Potential implications for breast cancer immune surveillance and HER2-targeted therapy resistance
    Thaler, Sonja
    Schad, Arno
    Kirkpatrick, Charles James
    Sleeman, Jonathan P.
    Springer, Erik
    Schmidt, Marcus
    Cotarelo, Cristina L.
    CANCER RESEARCH, 2018, 78 (04)
12345